Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial

W G Ondo, R Fayle, F Atassi, J Jankovic

Background: Excessive daytime somnolence (EDS) commonly complicates Parkinson’s disease (PD). The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions.

Method: A double blind, placebo controlled parallel design trial was conducted to assess the efficacy of modafinil (200–400 mg/day) for the treatment of EDS in PD. The primary efficacy measure was the Epworth Sleepiness (ES) scale score. Secondary efficacy points included the Unified Parkinson’s Disease Rating Scale (UPDRS), the Fatigue Severity Scale, the Hamilton Depression Scale, and the multiple sleep latency test (MSLT).

Results: Of a total of 40 subjects (29 men, mean (SD) age 64.8 (11.3) years), randomised to modafinil or placebo, 37 completed the study. Modafinil failed to significantly improve ES scores compared with placebo (2.7 v 1.5 points improvement, respectively, p = 0.28). MSLT failed to improve with modafinil relative to placebo (−0.16 v −0.70, respectively, p = 0.14). UPDRS, global impressions, Fatigue Severity Scale, and Hamilton Depression Scale scores were unchanged. Adverse events were minimal.

Conclusion: Modafinil failed to significantly improve EDS in PD compared with placebo. The drug did not alter motor symptoms in PD and was well tolerated.

Excessive daytime somnolence (EDS) occurs frequently in patients with Parkinson’s disease (PD). In our evaluation of 303 consecutive PD patients seen at the Baylor College of Medicine, we found that 50.2% reported pathologica sleepiness with Epworth Sleepiness (ES) scores of greater than 10. The aetiology of EDS is probably multifactorial, but in our series EDS correlated with worse PD, a longer duration of PD, male sex, and the use of dopamine agonists. Other reports and series have confirmed the frequent occurrence of EDS and other sleep problems in PD and reduced levels of hypocretin in cerebrospinal fluid. Although disturbed nocturnal sleep is common in PD, it does not usually correlate with EDS.

Modafinil is a wake-promoting agent originally developed for the treatment of narcolepsy. It has also been shown to potentially improve wakefulness in a variety of neurological conditions including PD. This broad spectrum of clinical action, including diseases of primary somnolence (narcolepsy) and somnolence secondary to poor nocturnal sleep (sleep apnoea), suggests that its effects are not specific to the aetiology of the EDS. The mechanism of action is not clearly understood because the drug has little affinity for most major neurotransmitter receptors including dopamine. Modafinil mostly binds in the amygdala and anterior hypothalamus, indicating the tuberomammillary nucleus. The basis of the well documented antipsoriatic effects of modafinil (Provigil; Cephalon, Frazer, PA), we designed a double blind, placebo controlled parallel trial to determine whether modafinil is effective in reversing daytime sleepiness in patients with PD.

METHODS
The Baylor College of Medicine institutional review board approved the protocol. We recruited patients meeting the diagnosis of PD from the Baylor College of Medicine Parkinson’s Disease Center and Movement Disorders Clinic. All subjects satisfied the diagnostic criteria for PD, were between 35 and 80 years of age, and reported daytime somnolence as measured by an ES score of greater than 10. Patients with serious medical conditions, known narcolepsy, known sleep apnoea, and pregnancy were excluded. The subjects were not allowed to take prescription stimulant medications.

We collected demographic data, including a composite dopaminergic dose using the formula: dose = levodopa/100 + controlled release levodopa/130 + pramipexole/1 + pergolide/0.75 + ropinirole/3.5. If entacapone or tolcapon was used, we increased the levodopa dose by 10%. Other PD medications were not included in the formula.

We felt this best captures the daytime sleep problems experienced by most patients with PD. Secondary endpoints included the Unified Parkinson’s Disease Rating Scale (UPDRS), the Fatigue Severity Scale, the Hamilton Depression Scale, global impressions, and the Medical Outcome Survey Short Form 36 (SF-36) Quality of Life scale. We also systematically assessed adverse events. The subjects also underwent a standard multiple sleep latency test (MSLT) in the morning (naps at 9 am, 11 am, 1 pm, 3 pm) at baseline and after treatment. Sleep onset was scored at the first epoch of any identifiable stage of sleep after lights out. Subjects also completed a sleep survey, including their subjective report of the previous nights. Those with motor fluctuations also completed a one day “on/off” diary just before starting the study drug and one day before their final evaluation. The UPDRS part III motor examinations were done in the “on” state. If subjects were fluctuators, the UPDRS part II activities of daily living scores were calculated by averaging the “on” and “off” scores.

Abbreviations: EDS, excessive daytime somnolence; ES, Epworth Sleepiness (score); MSLT, multiple sleep latency test; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale
After signing informed consent and baseline assessments including the MSLT, the subjects were randomised by a computerised randomisation code to receive either modafinil or placebo in a 1:1 ratio. Both the drug and the placebo, which matched the drug in taste and appearance, were supplied by Cephalon Inc. and distributed to the coordinator by another coordinator who was shielded from the subjects and not otherwise involved in the study in any way. The subjects began taking modafinil, one pill of 100 mg, or matching placebo, upon waking and at lunch (200 mg/day). After one week, the dose was increased to two pills twice a day (400 mg/day). One week later, we administered the ES (n = 40) (table 1). Three subjects dropped out: two men, both of whom were taking placebo (one due to acute illness and subsequent death from acute myelogenous leukaemia and the other due to his spouse’s serious illness that prevented his return), and one woman, who was on modafinil (who stopped due to instructions by her local physician to stop “study medication” because of back pain). All three dropped out prior to any post-drug evaluation. The remaining 37 patients completed all assessments.

There was no significant change in the primary endpoint, the ES score. Subjects on modafinil showed an improvement of 2.7 points compared with those on placebo who improved by 1.5 points (p = 0.28). MSLT results were not significantly different although the scores worsened less with modafinil (−0.16 (3.59) minutes) than with placebo (−0.70 (3.28) minutes), p = 0.14 (table 2). The UPDRS, Fatigue Severity Scale, Hamilton Depression Scale, SF-36, and global impression scores did not significantly change compared to baseline values. We analysed the change from baseline at all scheduled visits and last visit in the above mentioned efficacy variables using an analysis of covariance (ANCOVA) model with treatment and baseline values in the model. The proportion of Fatigue Severity Scale and global impression responders were analysed using a chi^2 test or Fisher’s exact test if warranted. The global impression response at the last visit was analysed using the Cochran–Manuel–Haenszel test. The normality assumption was examined for each continuous efficacy variable. If the assumption was not satisfied (p value from the Shapiro–Wilk test < 0.10), equivalent non-parametric techniques were applied on the variable. Specifically, a non-parametric ANCOVA was performed using the rank scores for the change from baseline scores and the baseline values in the model. All statistical comparisons were two tailed with a level of significance set at α = 0.05. For all the ANCOVA, we used type III sums of squares for the statistical inference.

We conducted a power analysis to determine the minimum sample size needed to detect a four point ES score difference between two groups. Based on the mean (SD) of qualifying subjects (ES>10) from our survey population of 303 patients with PD^1 we required a total of 28 (14 per group) participants to achieve a power of 0.81 at α = 0.05 (two tailed).

**RESULTS**

There were no significant differences in any demographic or baseline variables between the subjects assigned to the study drug and placebo (table 1). There were no significant differences in any demographic or baseline variables between the subjects assigned to the study drug and placebo (table 1).

### Table 1: Demographic and entry data (n = 40)

<table>
<thead>
<tr>
<th></th>
<th>Modafinil (n = 20)</th>
<th>Placebo (n = 20)</th>
<th>Entire group (n = 40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)*</td>
<td>64.4 (10.4)</td>
<td>65.1 (12.3)</td>
<td>64.8 (11.3)</td>
</tr>
<tr>
<td>Sex (men/women)</td>
<td>13/7</td>
<td>13/7</td>
<td>29/11</td>
</tr>
<tr>
<td>Duration of Parkinson’s disease*</td>
<td>6.5 (5.5)</td>
<td>7.0 (4.6)</td>
<td>6.8 (5.0)</td>
</tr>
<tr>
<td>Dopaminergic dose (mg/day)*</td>
<td>7.3 (3.5)</td>
<td>9.5 (5.2)</td>
<td>8.5 (4.6)</td>
</tr>
<tr>
<td>Fluctuating response</td>
<td>5/20</td>
<td>7/20</td>
<td>12/40</td>
</tr>
<tr>
<td>UPDRS activities of daily living</td>
<td>12.9 (5.5)</td>
<td>14.4 (6.0)</td>
<td>13.7 (5.8)</td>
</tr>
<tr>
<td>UPDRS motor*</td>
<td>24.1 (9.8)</td>
<td>29.2 (9.5)</td>
<td>26.7 (9.8)</td>
</tr>
<tr>
<td>Epworth score*</td>
<td>15.8 (3.0)</td>
<td>15.9 (3.5)</td>
<td>15.8 (3.2)</td>
</tr>
</tbody>
</table>

*Data are mean (SD). UPDRS, Unified Parkinson’s Disease Rating Scale.

### Table 2: Efficacy data (n = 37)*

<table>
<thead>
<tr>
<th></th>
<th>Modafinil (n = 19)</th>
<th>Placebo (n = 18)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Visit 1</td>
<td>Visit 2</td>
</tr>
<tr>
<td>Epworth Scale</td>
<td>15.7 (3.1)</td>
<td>13.5 (4.8)</td>
</tr>
<tr>
<td>UPDRS activities of daily living</td>
<td>12.5 (5.4)</td>
<td>12.7 (5.6)</td>
</tr>
<tr>
<td>UPDRS motor</td>
<td>23.9 (10.0)</td>
<td>23.7 (9.5)</td>
</tr>
<tr>
<td>Multiple sleep latency test (mean minutes)</td>
<td>9.9 to 15.1</td>
<td>9.9 to 15.5</td>
</tr>
<tr>
<td>Short Form–36</td>
<td>19.1 to 28.7</td>
<td>19.1 to 28.2</td>
</tr>
<tr>
<td>Fatigue Severity Scale</td>
<td>6.4 (5.1)</td>
<td>4.9 (3.6)</td>
</tr>
<tr>
<td>Fatigue Severity Scale</td>
<td>3.9 to 8.8</td>
<td>3.1 to 6.6</td>
</tr>
<tr>
<td>Fatigue Severity Scale</td>
<td>37.6 (14.1)</td>
<td>36.7 (12.7)</td>
</tr>
<tr>
<td>Fatigue Severity Scale</td>
<td>20.8 to 44.4</td>
<td>30.7 to 42.9</td>
</tr>
<tr>
<td>Hamilton Depression Scale</td>
<td>6.5 (5.0)</td>
<td>5.5 (4.6)</td>
</tr>
<tr>
<td>Hamilton Depression Scale</td>
<td>4.1 to 8.9</td>
<td>3.3 to 7.8</td>
</tr>
<tr>
<td>Change in sleepiness “much or very much improved”</td>
<td>6/19 (32%)</td>
<td>4/18 (22%)</td>
</tr>
</tbody>
</table>

*Data are mean (SD) and 95% confidence intervals. †None of the subsections of the SF-36 significantly improved compared with placebo. All comparisons: p >0.05. UPDRS, Unified Parkinson’s Disease Rating Scale.
placebo. In fluctuating subjects, there was no change in on/off time (table 2).

The medication was well tolerated in our patients. Only one patient taking modafinil elected to return to the lower dose, secondary to nausea and anxiety. Other adverse events thought to be at least possibly related to drug included dry mouth (n = 1), dizziness (n = 1), and back pain (n = 1). Adverse events recorded in subjects taking placebo included hypotension requiring hospitalisation and reduction of antihypertensive medications (n = 1), renal calcinosis (n = 1), and blurred vision (n = 1).

DISCUSSION
This double blind, placebo controlled study of patients with PD failed to show a significant reduction of daytime somnolence as measured by ES, the primary endpoint. Secondary outcome measures such as MSLT, Fatigue Severity Scale, Hamilton Depression Scale, and global impression scores also showed no difference between modafinil and placebo. The PD motor status was not affected and adverse events were minimal.

These results contrast with the results of two other controlled trials that have reported significantly improved ES in patients with EDS associated with PD.20 21 Both trials were crossover, smaller, and of shorter duration, although Adler et al’s study was re-analysed as a parallel design using the first arm due to a large carry-over effect. Neither reported a power analysis. Patient demographics (age, sex ratio, duration of PD) were similar to our study, although baseline sleepiness was less severe in Hogl et al’s study.21 The dose of modafinil in both studies was actually lower than in ours. The actual improvement in ES on drug was 2.7 in our study, compared with 3.3 and 3.4 in the others. The placebo response was also slightly greater in our study resulting in a smaller overall treatment effect (1.2 in ours v 2.6 and 4.7 in the others). The greater placebo response may have resulted from the twice daily dosing.

The PD subjects enrolled in our study demonstrated marked EDS as determined by MSLT and ES. Both measures were similar to severity to those seen in narcolepsy patients.25 26 27 In contrast with narcolepsy, however, only four of our subjects demonstrated any early onset rapid eye movement period (EOREMP). In those four subjects, 9/32 of our subjects demonstrated any early onset rapid eye movements (EOREM). In those four subjects, 9/32

REFERENCES

11th European Forum on Quality Improvement in Health Care
26–28 April 2006, Prague, Czech Republic
For further information please go to: www.quality.bmj.org
Book early to benefit from a discounted delegate rate